Scarica l'app Stockscreener
38.15
0.24%
0.0946
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EXEL Giù?
Forum
Previsione
Precedente Chiudi:
$38.06
Aprire:
$37.81
Volume 24 ore:
2.34M
Relative Volume:
0.88
Capitalizzazione di mercato:
$10.27B
Reddito:
$2.17B
Utile/perdita netta:
$521.27M
Rapporto P/E:
21.56
EPS:
1.77
Flusso di cassa netto:
$633.79M
1 W Prestazione:
-4.80%
1M Prestazione:
-4.84%
6M Prestazione:
-3.66%
1 anno Prestazione:
+11.26%
Intervallo 1D:
$37.58
$38.90
Intervallo di 1 settimana:
$36.00
$40.24
Portata 52W:
$31.90
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Nome
Exelixis Inc
Settore
Industria
Telefono
(650) 837-7000
Indirizzo
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Confronta EXEL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
38.15 | 10.25B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.80 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.02 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.55 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
836.27 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.19 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | Ripresa | Barclays | Equal Weight |
| 2025-09-17 | Ripresa | Barclays | Equal Weight |
| 2025-09-17 | Iniziato | Goldman | Buy |
| 2025-07-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2024-09-19 | Iniziato | UBS | Neutral |
| 2024-04-11 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Iniziato | BTIG Research | Buy |
| 2023-12-15 | Iniziato | Citigroup | Buy |
| 2023-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-22 | Reiterato | Oppenheimer | Outperform |
| 2023-08-08 | Iniziato | SVB Securities | Market Perform |
| 2023-07-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Ripresa | Piper Sandler | Overweight |
| 2023-03-09 | Iniziato | Wells Fargo | Overweight |
| 2023-01-26 | Iniziato | Credit Suisse | Outperform |
| 2022-10-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-11-03 | Ripresa | Jefferies | Buy |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-18 | Ripresa | Goldman | Sell |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-03-18 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Iniziato | Goldman | Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Underweight |
| 2018-05-11 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-16 | Reiterato | SunTrust | Buy |
| 2017-09-22 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-09-12 | Reiterato | Needham | Buy |
| 2017-07-14 | Iniziato | SunTrust | Buy |
| 2017-03-31 | Iniziato | Needham | Buy |
| 2017-03-16 | Iniziato | Oppenheimer | Perform |
| 2017-02-28 | Downgrade | Stifel | Buy → Hold |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2016-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Reiterato | Stifel | Buy |
Mostra tutto
Exelixis Inc Borsa (EXEL) Ultime notizie
How Exelixis Inc. stock trades before earnings2025 Geopolitical Influence & Free Real-Time Volume Trigger Notifications - newser.com
Can you recover from losses in Exelixis Inc.2025 Price Action Summary & Fast Entry Momentum Alerts - newser.com
How Exelixis Inc. stock trades during market volatilityEarnings Summary Report & Weekly Market Pulse Updates - newser.com
Can Exelixis Inc. stock weather global recessionMarket Weekly Review & Safe Capital Growth Trade Ideas - newser.com
Can Exelixis Inc. (EX9) stock retain market dominanceRate Cut & High Win Rate Trade Tips - newser.com
Using data filters to optimize entry into Exelixis Inc.Weekly Gains Summary & Detailed Earnings Play Strategies - newser.com
Key metrics from Exelixis Inc.’s quarterly dataEarnings Recap Report & Weekly Top Gainers Alerts - newser.com
Using RSI to spot recovery in Exelixis Inc.Weekly Investment Report & Weekly Stock Performance Updates - newser.com
Exelixis Shares Fall After Guggenheim Downgrade - MarketScreener
EXEL Downgraded to Neutral by Guggenheim on November 3, 2025 | E - GuruFocus
Real time alert setup for Exelixis Inc. performanceM&A Rumor & Weekly High Conviction Ideas - newser.com
Will Exelixis Inc. (EX9) stock rise with strong economyQuarterly Profit Report & Real-Time Volume Analysis Alerts - newser.com
Guggenheim Downgrades Exelixis to Neutral From Buy - MarketScreener
How Exelixis Inc. (EX9) stock reacts to Fed tightening2025 Buyback Activity & Expert Approved Trade Ideas - newser.com
How to escape a deep drawdown in Exelixis Inc.July 2025 Summary & Free Daily Entry Point Trade Alerts - newser.com
Exelixis Inc. stock trend forecast2025 Bull vs Bear & Risk Controlled Stock Pick Alerts - newser.com
Can Exelixis Inc. stock beat market expectations this quarterJuly 2025 Market Mood & Precise Buy Zone Tips - newser.com
Understanding Exelixis Inc.’s price movement2025 Market Sentiment & Weekly Stock Breakout Alerts - newser.com
How Exelixis Inc. (EX9) stock reacts to new regulationsIndex Update & Free Low Drawdown Momentum Trade Ideas - newser.com
How Exelixis Inc. (EX9) stock reacts to monetary easing2025 Dividend Review & Weekly Top Gainers Alerts - newser.com
Exelixis Q2 2025 slides: cabozantinib franchise grows 19% YoY, NET launch gains traction - Investing.com Nigeria
Why Exelixis Inc. is moving todayMarket Trend Summary & Daily Momentum Trading Reports - newser.com
Why Exelixis Inc. stock could benefit from AI revolutionEarnings Beat & AI Optimized Trade Strategies - newser.com
Will Exelixis Inc. (EX9) stock beat Nasdaq index returns2025 Analyst Calls & Growth Focused Entry Reports - newser.com
Will Exelixis Inc. benefit from macro trends2025 Technical Patterns & Risk Controlled Swing Alerts - newser.com
Exelixis Q2 2025 slides: cabozantinib franchise grows 19% YoY, NET launch gains traction By Investing.com - Investing.com South Africa
Earnings call transcript: Exelixis Q2 2025 sees solid revenue growth By Investing.com - Investing.com Philippines
Earnings call transcript: Exelixis Q2 2025 sees solid revenue growth - Investing.com
Is Exelixis Inc. stock cheap at current valuation2025 Geopolitical Influence & Community Consensus Trade Signals - newser.com
What recovery options are there for Exelixis Inc.Quarterly Profit Report & Free Technical Pattern Based Buy Signals - newser.com
Exelixis Inc expected to post earnings of 61 cents a shareEarnings Preview - TradingView
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Exelixis (EXEL) - The Globe and Mail
Exelixis Inc Stock Analysis and ForecastStock Market Trends & Small Investment Growth Plans - earlytimes.in
Exelixis' Q4 Loss Widens as Investors Await Key Trial Data - AOL.com
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer - GlobeNewswire Inc.
Exelixis Inc Azioni (EXEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.14%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):